Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study to Evaluate Switching From a Regimen Consisting of the Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (STR) to the Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate STR

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Gilead Sciences
ClinicalTrials.gov Identifier:
NCT01286740
First received: January 27, 2011
Last updated: April 19, 2013
Last verified: April 2013

January 27, 2011
April 19, 2013
January 2011
July 2011   (final data collection date for primary outcome measure)
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 12 (FDA Snapshot Analysis) [ Time Frame: Week 12 ] [ Designated as safety issue: No ]
The percentage of participants with HIV-1 RNA < 50 copies/mL at Week 12 was analyzed using the FDA snapshot analysis.
The primary efficacy endpoint is the proportion of subjects who have HIV-1 RNA < 50 copies/mL at Week 12 [ Time Frame: 12 Weeks ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01286740 on ClinicalTrials.gov Archive Site
  • Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 (FDA Snapshot Analysis) [ Time Frame: Week 24 ] [ Designated as safety issue: No ]
    The percentage of participants with HIV-1 RNA < 50 copies/mL at Week 24 was analyzed using the FDA snapshot analysis.
  • Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 (FDA Snapshot Analysis) [ Time Frame: Week 48 ] [ Designated as safety issue: No ]
    The percentage of participants with HIV-1 RNA < 50 copies/mL at Week 48 was analyzed using the FDA snapshot analysis.
  • Plasma Concentration of RPV and EFV at Week 1 [ Time Frame: Week 1 ] [ Designated as safety issue: No ]
    The mean (SD) plasma concentration (ng/mL) of RPV and EFV was measured at Week 1.
  • Plasma Concentration of RPV and EFV at Week 2 [ Time Frame: Week 2 ] [ Designated as safety issue: No ]
    The mean (SD) plasma concentration (ng/mL) of RPV and EFV was measured at Week 2.
  • Plasma Concentration of RPV and EFV at Week 4 [ Time Frame: Week 4 ] [ Designated as safety issue: No ]
    The mean (SD) plasma concentration (ng/mL) of RPV and EFV was measured at Week 4.
  • Plasma Concentration of RPV and EFV at Week 6 [ Time Frame: Week 6 ] [ Designated as safety issue: No ]
    The mean (SD) plasma concentration (ng/mL) of RPV and EFV was measured at Week 6.
  • Plasma Concentration of RPV and EFV at Week 8 [ Time Frame: Week 8 ] [ Designated as safety issue: No ]
    The mean (SD) plasma concentration (ng/mL) of RPV and EFV was measured at Week 8.
  • Plasma Concentration of RPV at Week 12 [ Time Frame: Week 12 ] [ Designated as safety issue: No ]
    The mean (SD) plasma concentration (ng/mL) of RPV was measured at Week 12.
  • Plasma Concentration of EFV at Week 12 [ Time Frame: Week 12 ] [ Designated as safety issue: No ]
    The mean (SD) plasma concentration (ng/mL) of EFV was measured at Week 12. No analyses of EFV plasma concentrations were conducted after Week 12
  • Plasma Concentration of RPV at Week 24 [ Time Frame: Week 24 ] [ Designated as safety issue: No ]
    The mean (SD) plasma concentration (ng/mL) of RPV was measured at Week 24.
  • Plasma Concentration of RPV at Week 36 [ Time Frame: Week 36 ] [ Designated as safety issue: No ]
    The mean (SD) plasma concentration (ng/mL) of RPV was measured at Week 36.
  • Plasma Concentration of RPV at Week 48 [ Time Frame: Week 48 ] [ Designated as safety issue: No ]
    The mean (SD) plasma concentration (ng/mL) of RPV was measured at Week 48.
The secondary endpoint is to evaluate the safety and tolerability of FTC/RPV/TDF STR over 48 weeks [ Time Frame: 48 Weeks ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Study to Evaluate Switching From a Regimen Consisting of the Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (STR) to the Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate STR
A Phase 2B Open Label Pilot Study to Evaluate Switching From a Regimen Consisting of a Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Single Tablet Regimen (STR) to Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF) STR in Virologically Suppressed, HIV 1 Infected Subjects

The purpose of this Phase 2b study was to evaluate the efficacy and safety of the emtricitabine/rilpivirine/tenofovir disoproxil fumarate (FTC/RPV/TDF) STR, after switching from the efavirenz (EFV)/FTC/TDF STR at baseline, in maintaining HIV-1 RNA < 50 copies/mL at Week 12. HIV-infected patients were enrolled if they had received EFV/FTC/TDF for ≥ 3 months prior to study start, were experiencing safety or tolerability concerns (in particular, EFV-related intolerance), and wished to change to an alternate, better-tolerated regimen.

Not Provided
Interventional
Phase 2
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
HIV-1 Infection
Drug: FTC/RPV/TDF
Emtricitabine (FTC) 200 mg/rilpivirine (RPV) 25 mg/tenofovir disoproxil fumarate (tenofovir DF; TDF) 300 mg single-tablet regimen (STR) administered orally with a meal once daily
Other Names:
  • Complera
  • Eviplera
Experimental: FTC/RPV/TDF
Participants switched from their existing treatment regimen of EFV/FTC/TDF to the FTC/RPV/TDF STR.
Intervention: Drug: FTC/RPV/TDF
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
50
March 2012
July 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Ability to understand and sign a written informed consent form
  • Receiving EFV/FTC/TDF continuously for ≥ 3 months preceding the screening visit
  • Plasma HIV-1 RNA concentrations (at least two measurements) at undetectable levels for ≥ 8 weeks prior to the screening visit and HIV-1 RNA < 50 copies/mL at the screening visit
  • On their first antiretroviral drug regimen, and no HIV-1 RNA > 50 copies/mL measured at two consecutive time points after first achieving HIV RNA < 50 copies/mL
  • Had a genotype prior to starting FTC/RPV/TDF and no known resistance to any of the study agents
  • Normal ECG
  • Hepatic transaminases (AST and ALT) ≤ 5 x upper limit of normal (ULN)
  • Total bilirubin ≤ 1.5 mg/dL, or normal direct bilirubin
  • Adequate hematologic function (absolute neutrophil count ≥ 1,000/mm^3; platelets ≥ 50,000/mm^3; hemoglobin ≥ 8.5 g/dL)
  • Serum amylase ≤ 5 x ULN (subjects with serum amylase > 5 x ULN eligible if serum lipase ≤ 5 x ULN)
  • Adequate renal function (estimated glomerular filtration rate ≥ 50 mL/min according to the Cockcroft-Gault formula)
  • Males and Females of childbearing potential must have agreed to utilize highly effective contraception methods (two separate forms of contraception, one of which must be an effective barrier method, or be nonheterosexually active, practice sexual abstinence, or have a vasectomized partner) from screening throughout the duration of the study period and for 60 days following the last dose of study drug.
  • Age ≥ 18 years
  • Life expectancy ≥ 1 year

Exclusion Criteria:

  • A new AIDS-defining condition diagnosed within 21 days prior to screening
  • Females who were breastfeeding
  • Positive serum pregnancy test (female of childbearing potential)
  • Proven or suspected acute hepatitis in the 21 days prior to study entry
  • Subjects receiving drug treatment for Hepatitis C, or subjects anticipated to receive treatment for Hepatitis C during the course of the study, or with a history of liver disease
  • Was experiencing decompensated cirrhosis
  • Implanted defibrillator or pacemaker
  • Current alcohol or substance abuse judged by the Investigator to potentially interfere with subject compliance
  • History of malignancy within the past 5 years or ongoing malignancy other than cutaneous Kaposi's sarcoma, basal cell carcinoma, or resected, noninvasive cutaneous squamous carcinoma
  • Active, serious infections requiring parenteral antibiotic or antifungal therapy within 21 days prior to Baseline
  • All investigational drugs
  • Ongoing therapy or anticipated need to initiate drugs or herbal/natural supplements during the study that were contraindicated or not recommended for use as indicated in the protocol, including drugs not to be used with FTC, RPV, and TDF; or subjects with known allergies to the excipients of the FTC/RPV/TDF STR
  • Participation in any other clinical trial without prior approval from the sponsor was prohibited while participating in this trial
  • Treatment with immunosuppressant therapies or chemotherapeutic agents within 3 months of study screening, or expected to receive these agents or systemic steroids during the study (eg, corticosteroids, immunoglobulins, and other immune- or cytokine-based therapies)
  • Any other clinical condition or prior therapy that, in the opinion of the Investigator, would make the subject unsuitable for the study or unable to comply with the dosing requirements
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01286740
GS-US-264-0111
No
Gilead Sciences
Gilead Sciences
Not Provided
Study Director: David Pugatch, MD Gilead Sciences
Gilead Sciences
April 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP